Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
TROPION-PanTumor02
A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)
- NCT05460273 ↗
- Active, not recruiting
- AstraZeneca
- Focused
We haven't built an HCP commentary report on TROPION-PanTumor02 (datopotamab deruxtecan in advanced solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TROPION-PanTumor02 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- Phase 1/2, Multicentre, Open-label, Multiple-cohort Study of Dato-DXd in Chinese Patients With Advanced Non-small-cell Lung Cancer, Triple-negative Breast Cancer, Gastric/Gastroesophageal Junction Cancer, Urothelial Cancer, and Other Solid Tumours (TROPION-PanTumor02)
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung; Triple Negative Breast Cancer
- Interventions
- Datopotamab Deruxtecan (Dato-DXd)
- Arms
- Dato-DXd Arm · Experimental
- Enrollment
- 119
- Primary outcomes
- Confirmed Objective Response Rate(ORR) Assessed by Independent Central Review(ICR)
- Sponsor
- AstraZeneca with Daiichi Sankyo
- Start
- Jul 11, 2022
- Primary completion
- Nov 7, 2023
- Results posted
- Yes
- Registry record
- NCT05460273 · updated Aug 31, 2026